Doxiverse Staff - August 2026
GE HealthCare announced on August 3 the U.S. launch of Invenia ABUS Prime, an automated breast ultrasound (ABUS) system for supplemental screening in women with dense breasts, alongside ABUS StreamVue, a newly FDA-cleared, browser-based viewer that lets radiologists read ABUS exams remotely.
Why it matters: Breast imaging programs looking to scale supplemental ultrasound screening across multiple sites have had to rely on dedicated workstation software for reading exams - StreamVue's remote, browser-based access removes that specific deployment barrier, while Prime adds AI-assisted tools aimed at scan consistency and reading speed.
What Happened
GE HealthCare's release states that Invenia ABUS Prime has received FDA Premarket Approval (PMA) - a more rigorous regulatory pathway than the more common 510(k) clearance - and CE Marking, while ABUS StreamVue, the enterprise viewer built in collaboration with Candelis, has received separate FDA 510(k) clearance and CE Marking. These are two distinct regulatory approvals for two different parts of the system: the scanning device (Prime) and the remote-reading software (StreamVue).
The company describes several AI-enabled features in Invenia ABUS Prime: a "Scan Quality Assessment" and "Auto Nipple Detection" tool built on GE's Verisound AI, intended to support consistent, reproducible scans; a "Fast Scan" tool the company says increases scan speed by up to 40% compared with the prior-generation Invenia ABUS 2.0; and AI-assisted reading support powered by QVCAD, a third-party tool from QView Medical. GE cites two external studies to support QVCAD's performance a Radiology study on reading time with and without computer-aided detection for automated breast ultrasound, and an AJR (American Journal of Roentgenology) study on interpretation time using a concurrent-read CAD system for dense-breast ultrasound screening reporting up to a 33% reduction in reading time and up to 93% sensitivity for lesion detection.
One of the first U.S. installations of Invenia ABUS Prime is at BeSound, a breast imaging provider in Los Angeles, which is also planning a mobile screening unit. GE HealthCare's release separately cites the BRAID trial (published in Insights into Imaging, 2026), an independent study reporting that ABUS showed higher patient acceptance and a more positive experience compared with other supplemental screening techniques for dense breasts.
Russ Behler, GE HealthCare's Global Product Director for LOGIQ Ultrasound, said in the release that the StreamVue solution supports remote review, more standardized presentation, and simpler deployment across care settings.
What This Means for Breast Imaging Programs
For imaging networks already using or considering ABUS for dense-breast supplemental screening, StreamVue's browser-based remote reading could reduce the IT overhead of standardizing exam review across multiple sites, since it doesn't require installing dedicated workstation software at each location. The AI-assisted scan-quality and reading tools are positioned as workflow aids rather than autonomous diagnostic tools - the release frames QVCAD as designed to "streamline review," not replace radiologist interpretation.
What's Still Unsettled
The specific "33% reduction in reading time" and "up to 93% sensitivity" figures GE cites come from two published, peer-reviewed studies of CAD-assisted automated breast ultrasound reading generally, but based on the citation details in GE's release, those studies appear to predate this specific 2026 product generation (one of the cited DOIs corresponds to a 2019 Radiology publication). That means these figures are real, peer-reviewed data points about CAD-assisted ABUS reading as a category, but could not confirm that they represent a direct performance validation of the current Invenia ABUS Prime / QVCAD combination as deployed in 2026. Readers evaluating this system should ask GE or QView Medical directly for performance data specific to the current product version.
Separately, the BRAID trial finding on patient acceptance is real and independently published, but it evaluated ABUS as a screening modality broadly, it is not a study of this specific GE product line. And as with any recent product launch, real-world performance and workflow data from a broader base of U.S. sites beyond the initial BeSound installation is not yet available.
Sources:
- GE HealthCare press release, BusinessWire, August 3, 2026. https://www.businesswire.com/news/home/20260803008444/en/GE-HealthCare-expands-breast-imaging-portfolio-with-Invenia-ABUS-Prime-and-launch-of-ABUS-StreamVue
- Cited within GE's release: Performance and Reading Time of Automated Breast US with or without Computer-Aided Detection, Radiology, DOI: 10.1148/radiol.2019181816
- Cited within GE's release: Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women with Dense Breast Tissue, AJR, DOI: 10.2214/AJR.18.19516
- Cited within GE's release: Allajbeu et al., "Acceptance, experience, and feedback for supplemental screening in dense breasts among women participating in the BRAID trial," Insights into Imaging 17:14 (2026), DOI: 10.1186/s13244-025-02170-8